Keybank National Association OH Sells 89 Shares of argenx SE (NASDAQ:ARGX)

Keybank National Association OH cut its holdings in shares of argenx SE (NASDAQ:ARGX) by 5.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,699 shares of the company’s stock after selling 89 shares during the period. Keybank National Association OH’s holdings in argenx were worth $1,045,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Whipplewood Advisors LLC bought a new position in shares of argenx during the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC boosted its stake in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in shares of argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after purchasing an additional 61 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of argenx during the fourth quarter valued at approximately $66,000. Finally, Nkcfo LLC bought a new position in shares of argenx during the fourth quarter valued at approximately $68,000. 60.32% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Evercore ISI increased their target price on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Deutsche Bank Aktiengesellschaft cut shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price for the company in a research report on Tuesday, November 12th. Robert W. Baird increased their target price on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Oppenheimer increased their target price on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $662.83.

argenx Price Performance

Shares of argenx stock opened at $594.21 on Friday. The firm has a fifty day moving average price of $642.09 and a 200 day moving average price of $593.03. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21. The stock has a market cap of $36.10 billion, a PE ratio of -675.24 and a beta of 0.58.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.